Treatment Patterns for and Characteristics of Headache in Children and Adolescents Aged 6-17 Years in Japan: A Retrospective Cross-Sectional and Longitudinal Analysis of Health Insurance Claims Data

• Published in: Life (Basel, Switzerland) Vol. 14; no. 1; p. 96
• Main Authors: Katsuki, Masahito, Matsumori, Yasuhiko, Ichihara, Taisuke, Yamada, Yuya, Kawamura, Shin, Kashiwagi, Kenta, Koh, Akihito, Goto, Tetsuya, Kaneko, Kazuma, Wada, Naomichi, Yamagishi, Fuminori
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.01.2024
• Subjects: acute mediations; Anti-inflammatory agents; Care and treatment; Cross-sectional studies; Disease prevention; Family physicians; Headache; Headaches; Health insurance; Inflammation; Insurance claims; Longitudinal studies; medication overuse headache; Migraine; Nonsteroidal anti-inflammatory drugs; Normal distribution; Pain; Pain in children; Patients; pediatric; Pediatrics; Prescription drugs; Prophylaxis; Tablets; Teenagers; Trends; triptans; Japan; medication overuse headache; migraine; triptans; acute mediations; pediatric
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life14010096

To investigate the prescription patterns for patients aged 6-17 years with headaches in the REZULT database. We cross-sectionally investigated (Study 1) the pattern of prescription and the proportion of triptan overprescription (≥30 tablets/90 d of triptans) among patients diagnosed with headaches in 2020. Next, we longitudinally studied patients (Study 2) for more than two years from the initial headache diagnosis (July 2010 to April 2022). The number of prescribed tablets was counted every 90 days. In Study 1, headache diagnoses were assigned to 62,568 of 543,628 (11.51%) patients, and 1524 of 62,568 (2.44%) patients received acute medication. Single nonsteroidal anti-inflammatory drugs and triptans were prescribed to 620/624 (99.36%) and 5/624 (0.80%) of patients aged 6-11 years, respectively, and 827/900 (91.89%) and 91/900 (10.11%) of patients aged 12-17 years, respectively. Triptan overprescription was observed in 11/96 (11.46%) patients, and 5/11 (45.45%) of those patients received prophylactic medication. In Study 2, 80,756/845,470 (9.55%) patients aged 6-17 years were diagnosed with headaches that persisted for at least two years. Over two years, 44/80,756 (0.05%) patients were overprescribed triptans, and 3408/80,756 (4.22%) patients were prescribed prophylaxis on at least one occasion. Based on real-world data, the appropriate use of prophylactic treatment is still problematic. Overprescription of triptans was observed, although the number of patients was small.